Performance of Ceftazidime-Avibactam 30/20-μg and 10/4-μg Disks for Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa

Ceftazidime-avibactam, a new β-lactam–β-lactamase inhibitor combination, is active against multidrug-resistant Enterobacterales and Pseudomonas aeruginosa isolates and has became available for clinical use in China in the latter half of 2019. In this study, we evaluated the performance of the disk d...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Renru, Shen, Siquan, Yin, Dandan, Ding, Li, Shi, Qingyu, Yang, Yang, Guo, Yan, Wu, Shi, Zhi, Peiyuan, Zhu, Demei, Hu, Fupin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100715/
https://www.ncbi.nlm.nih.gov/pubmed/36744897
http://dx.doi.org/10.1128/spectrum.02720-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100715/
https://www.ncbi.nlm.nih.gov/pubmed/36744897
http://dx.doi.org/10.1128/spectrum.02720-22

Ejemplares similares